Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial
Open Access
- 2 July 2025
- journal article
- Published by Elsevier in The Lancet HIV
- Vol. 12 (8) , e546-e555
Abstract
No abstract availableKeywords
Funding Information
- Universityof CapeTown
- Bill and Melinda Gates Foundation
- Wellcome Trust (221698/Z/20/Z)
This publication has 21 references indexed in Scilit:
- Optimizing antigen selection for the development of tuberculosis vaccinesCell Insight, 2024
- Final Analysis of a Trial of M72/AS01 E Vaccine to Prevent TuberculosisNew England Journal of Medicine, 2019
- Gender Norms and HIV Testing/Treatment Uptake: Evidence from a Large Population-Based Sample in South AfricaAIDS and Behavior, 2019
- Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or OlderThe Journal of Infectious Diseases, 2018
- A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian AdultsMedicine, 2016
- A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in AfricaNew England Journal of Medicine, 2015
- ART and prevention of HIV-associated tuberculosisThe Lancet HIV, 2015
- Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialThe Lancet, 2014
- Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled TrialsClinical Infectious Diseases, 2013
- Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trialVaccine, 2013